More News! AstraZeneca’s €2B Blowout & First Checkpoint Inhibitor

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura
  • AstraZeneca went in big for an artificial antibody-type protein in an up to €2B deal with a Boston-based company
  • GSK has injected $140M into its manufacturing expansion in Maryland
  • Word on the street is that Sanofi may be trying to acquire Sarepta
  • Another M&A rumour that Pfizer may try to acquire BMS has been reinvigorated by Pfizer’s Q1 report
  • Shire made a lucrative deal with North Carolina-based Parion to advance ophthalmology candidates
  • Qiagen is expanding into China via a partnership with Maccura
  • Novartis is adding to its NASH portfolio by availing itself of an exclusive licensing option for emricasan from Conatus
Oleksii G
  • AstraZeneca has brought its own checkpoint inhibitor to market
  • Novartis’ Rydapt has been approved for several more indications, including acute myeloid leukaemia and three more types of systemic mastocytosis
  • AlzProtect’s candidate, ASP2006, for Progressive Supranuclear Palsy has been granted Orphan Drug Designation by the FDA
  • Switzerland gave Pharmamar Orphan Drug Designation for Aplidin, its multiple myeloma treatment.
Brian Lasenby
  • After Abivax’s promising but very early-stage results, researchers in the US also had a breakthrough towards an HIV cure — but they’re using CRISPR.
  • Spanish researchers have found that phagocytosis not only clears useless cells but also educates the cannibals as they are imbued with protective properties from their prey.

Images from Brian Lasenby, Eric Axelson, Marco Diaz Segura, Oleksii G /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.